EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

EHA - Access to Medicine

By reporting the unavailability of hematology medicine you are strengthening our efforts to improve patients' access to medicine across Europe. REPORT NOW

Chairs and Members

Chair (2017-ongoing)Oliver A. Cornely—University Hospital Cologne, Cologne (Germany)

Co-chair (2023-ongoing)Livio Pagano—Fondazione Policlinico A.

EU commissioner Tonio Borg: 'we will continue to improve the life of people suffering from Thalassaemia'

 

Today, May 8, is International Thalassemia Day. Today, we seek to enhance the awareness and knowledge of thalassemia and other hemoglobin disorders.

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers: HARMONY Alliance is an unparalleled medicine offensive to battle blood cancers by using Big Data analyses.

EHA Grants Hall of Fame

SWG Educational Activities

EHA-SWG meeting at EHA2023Date and timeThursday, June 8, 2023, from 16. 00–18. 00. LocationFrankfurt, Germany. Chairs
A Taher
A Iolascon
EHA-SWG scientific meetingMeeting topic and title‘Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.